This program aims to develop anti-CD40L therapeutic monoclonal antibody for immuno-oncology. Anti-CD40L antibody targets CD40/TNFRSF5 receptors. It produces pleiotropic effects in various cells and biological processes, including immune response, thrombosis and atherogenesis. Data implicate that soluble CD40L is fully capable of activating DCs and inducing T-cell responses. The CD40L fusion protein can also trigger CD40-dependent B-cell proliferation. The use of agonistic anti-CD40L antibodies to induce CD40 signaling on DCs can substitute for CD4+ T-cell to help and directly stimulate a specific CD8+ CTL response, highlighting a clear rationale for CD40-based cancer immunotherapy. In this case, anti-CD40L antibody has great potential to be widely applied in the efficient treatment of various diseases. All the research results have been patented.
CD27
CD27 is a co-stimulatory receptor expressed in humans as naïve cell and central memory T cells. CD27 is progressively downregulated in effector memory cells. It plays a part in both primary and memory responses during viral infection, acting either independently or together with CD28 to promote primed CD8+ T cells survival. Multiple studies have shown that:
• Triggering of CD27 T-cell co-stimulatory signaling may be particularly applicable to, for example, ex vivo expansion of adoptive T-cells.
• Agonistic CD27 mAb can promote T-cell dependent tumor rejection, demonstrating that enhanced CD27
signaling can improve anti-tumor responses.
Fig.1 CD70/CD27-based agonists for cancer therapy.4
Anti-CD27 Antibody Research in Cancer Studies
CD27 is considered to be the most useful when working in a combination therapy rather than monotherapy. Here are the published data about CD27 as a potential target for cancer immunotherapy.
• Combination therapy of Anti-CD27 and CD20 mAb for melanoma.
Fig.2 Combination therapy of Anti-CD27 and CD20 mAb for melanoma.2
• Therapeutic potency of anti–4-1BBL and anti-CD27 mAb against lymphoma.
• Combination therapy of Anti-CD27 and PD-1/L1 mAb for melanoma.
Fig.3 Combination therapy of Anti-CD27 and PD-1/L1 mAb for melanoma.1
Indication
Based on the published data, we learn that CD27 is overproduced by various types of tumor such as B- and T-cell lymphomas, thyroid cancer, stomach cancer, and renal cancer. Therefore, we intend to develop multiple programs for different indications (not limited to one specific type of tumor), in which CD27 is highly expressed.
Clinical Trials under Progress
Currently, several anti-CD27 therapeutic monoclonal antibodies have been tested in clinical trials for several types of cancer. The growing number of agonistic mAbs that stimulate T cells have been identified. And some early clinical trial data show great potential. It should be noted that there are no significant data on phase II or phase III clinical trials.
In this case, CD27 still owns a promising market prospect in the future. In particular, there is increasing interest in combining anti-CD27 with other agents and achieving great success in the treatment of various cancers.
With our extensive experience in providing CRO services, we are confident about the streamlined end-to-end program development. We are committed to developing a complete program, ranging from antibody discovery, engineering, optimization, to pre-clinical studies for our partners within the timeline promised. Periodic progress will be delivered to our clients for effective, smooth and timely communication.
Fig.4 The timeline of Next-IO™ programs.
Creative Biolabs is looking for potential partners (including but not limited to major pharma or biotech firms) to develop anti-4-1BB monoclonal antibody program together. Our scientists are dedicated to bringing years of valuable experience to our partner and enabling a meaningful partnership. By doing so, we wish to help both sides to proceed with IND and many stages of clinical trials.
If you are interested in our program, please feel free to contact us to learn more
details about the
cooperation. Looking forward to working with you in the near future.
Download our brochure